These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 29304138)

  • 1. The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.
    Thakur SS; Li H; Chan AMY; Tudor R; Bigras G; Morris D; Enwere EK; Yang H
    PLoS One; 2018; 13(1):e0188983. PubMed ID: 29304138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
    Milburn M; Rosman M; Mylander C; Tafra L
    Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis.
    Ingoldsby H; Webber M; Wall D; Scarrott C; Newell J; Callagy G
    Breast; 2013 Oct; 22(5):879-86. PubMed ID: 23643806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of Oncotype Dx score with tumor grade, size, nodal status, proliferative marker Ki67 and Nottingham Prognostic Index in early breast cancer tumors in Saudi Population.
    Durrani S; Al-Mushawa F; Heena H; Wani T; Al-Qahtani A
    Ann Diagn Pathol; 2021 Apr; 51():151674. PubMed ID: 33360027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score.
    Robertson S; Acs B; Lippert M; Hartman J
    Breast Cancer Res Treat; 2020 Aug; 183(1):161-175. PubMed ID: 32572716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer.
    Tan AC; Li BT; Nahar K; Danieletto S; Fong ES; Currer T; Parasyn A; Middleton P; Wong H; Smart D; Rutovitz JJ; McCloud P; Hughes TM; Marx GM
    Asia Pac J Clin Oncol; 2018 Apr; 14(2):e161-e166. PubMed ID: 28960862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of the Ki67 Working Group prognostic risk categories with the Oncotype DX Recurrence Score in early breast cancer.
    Patel R; Hovstadius M; Kier MW; Moshier EL; Zimmerman BS; Cascetta K; Jaffer S; Sparano JA; Tiersten A
    Cancer; 2022 Oct; 128(20):3602-3609. PubMed ID: 35947048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
    Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience.
    Zhu X; Dent S; Paquet L; Zhang T; Graham N; Song X
    Eur J Cancer; 2014 Oct; 50(15):2544-9. PubMed ID: 25129366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of Ki-67 proliferative index with oncotype DX recurrence score in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer with low-burden axillary nodal disease - a review of 137 cases.
    Saad Abdalla Al-Zawi A; Anichkina KA; Elamass M; Aladili Z
    Pol J Pathol; 2024; 75(1):8-18. PubMed ID: 38741425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Prognostic Significance of the Oncotype DX Recurrence Score in T
    Wang M; Wu K; Zhang P; Zhang M; Ding A; Chen H
    Ann Surg Oncol; 2019 May; 26(5):1227-1235. PubMed ID: 30456680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progesterone receptor expression in proliferating cancer cells of hormone-receptor-positive breast cancer.
    Ueno T; Saji S; Chiba T; Kamma H; Isaka H; Itoh H; Imi K; Miyamoto K; Tada M; Sasano H; Toi M; Imoto S
    Tumour Biol; 2018 Nov; 40(10):1010428318811025. PubMed ID: 30841783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing?
    Allison KH; Kandalaft PL; Sitlani CM; Dintzis SM; Gown AM
    Breast Cancer Res Treat; 2012 Jan; 131(2):413-24. PubMed ID: 21369717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ki 67 assessment in breast cancer in an Egyptian population: a comparative study between manual assessment on optical microscopy and digital quantitative assessment.
    Ayad E; Soliman A; Anis SE; Salem AB; Hu P; Dong Y
    Diagn Pathol; 2018 Aug; 13(1):63. PubMed ID: 30153851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer.
    Gyanchandani R; Lin Y; Lin HM; Cooper K; Normolle DP; Brufsky A; Fastuca M; Crosson W; Oesterreich S; Davidson NE; Bhargava R; Dabbs DJ; Lee AV
    Clin Cancer Res; 2016 Nov; 22(21):5362-5369. PubMed ID: 27185370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?
    Auerbach J; Kim M; Fineberg S
    Arch Pathol Lab Med; 2010 Nov; 134(11):1697-701. PubMed ID: 21043825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reliability of Ki67 visual scoring app compared to eyeball estimate and digital image analysis and its prognostic significance in hormone receptor-positive breast cancer.
    Arun I; Venkatesh S; Ahmed R; Agrawal SK; Leung SCY
    APMIS; 2021 Aug; 129(8):489-502. PubMed ID: 34053140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nottingham-defined mitotic score: comparison with visual and image cytometric phosphohistone H3 labeling indices and correlation with Oncotype DX recurrence score.
    Zbytek B; Cohen C; Wang J; Page A; Williams DJ; Adams AL
    Appl Immunohistochem Mol Morphol; 2013 Jan; 21(1):48-53. PubMed ID: 22495373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of the Ki67 scoring categories in breast cancer subgroups.
    Niikura N; Masuda S; Kumaki N; Xiaoyan T; Terada M; Terao M; Iwamoto T; Oshitanai R; Morioka T; Tuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y
    Clin Breast Cancer; 2014 Oct; 14(5):323-329.e3. PubMed ID: 24492237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.